PriceTargets.com logo

NASDAQ:SCPS - Scopus BioPharma Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $20.00
  • Forecasted Upside: 327.35 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$4.68 As of 08/2/2021 01:00 AM ET
▲ +0.03 (0.65%)

This chart shows the closing price for SCPS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Scopus BioPharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SCPS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SCPS

Analyst Price Target is $20.00
▲ +327.35% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Scopus BioPharma in the last 3 months. The average price target is $20.00, with a high forecast of $20.00 and a low forecast of $20.00. The average price target represents a 327.35% upside from the last price of $4.68.

This chart shows the closing price for SCPS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 1 polled investment analysts is to hold stock in Scopus BioPharma.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/9/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/9/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/7/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/5/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/3/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
5/4/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
7/3/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
8/2/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/16/2021BenchmarkInitiated CoverageSpeculative Buy$20.00Low
(Data available from 8/2/2016 forward)

Scopus BioPharma

Scopus BioPharma Inc., a biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases. Its lead development programs are immuno-oncology gene therapy for the treatment of various cancers, which include CO-sTiRNA, a STAT3 inhibitor gene therapy that drives tumor cell growth and anti-tumor immune suppression; and MRI-1867, a cannabinoid-1 receptor inverse agonist and inhibitor of inducible nitric oxide synthase for the treatment of systemic sclerosis. Scopus BioPharma Inc. has strategic partnerships with the City of Hope, National Institutes of Health Program, and The Hebrew University of Jerusalem for its lead development and other programs. The company was formerly known as Project18 Inc. and changed its name to Scopus BioPharma Inc. in December 2017. Scopus BioPharma Inc. was incorporated in 2017 and is headquartered in New York, New York.
Read More

Today's Range

Now: $4.68
Low: $4.55
High: $4.90

50 Day Range

MA: $6.50
Low: $4.55
High: $9.59

52 Week Range

Now: $4.68
Low: $4.46
High: $47.86

Volume

66,803 shs

Average Volume

459,946 shs

Market Capitalization

$73.61 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Scopus BioPharma?

The following Wall Street research analysts have issued reports on Scopus BioPharma in the last twelve months: Benchmark Co..
View the latest analyst ratings for SCPS.

What is the current price target for Scopus BioPharma?

1 Wall Street analysts have set twelve-month price targets for Scopus BioPharma in the last year. Their average twelve-month price target is $20.00, suggesting a possible upside of 327.4%. Benchmark Co. has the highest price target set, predicting SCPS will reach $20.00 in the next twelve months. Benchmark Co. has the lowest price target set, forecasting a price of $20.00 for Scopus BioPharma in the next year.
View the latest price targets for SCPS.

What is the current consensus analyst rating for Scopus BioPharma?

Scopus BioPharma currently has 1 hold rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in SCPS, but not buy more shares or sell existing shares.
View the latest ratings for SCPS.

What other companies compete with Scopus BioPharma?

Other companies that are similar to Scopus BioPharma include MEI Pharma, Hamilton Thorne, Taiwan Liposome, Syros Pharmaceuticals, Sernova, Tristel, Conformis, CRH Medical, Co-Diagnostics, Wave Life Sciences, Akumin, Profound Medical, Sareum, Millendo Therapeutics and BELLUS Health.